Dipeptidyl peptidase-4 inhibition and narrow-band ultraviolet-B light in psoriasis (DINUP): study protocol for a randomised controlled trial.

Thumbnail
Name:
DINUPStudyProtocol.pdf
Size:
570.5Kb
Format:
PDF
Description:
OA Article
Download
Authors
Lynch, Maeve
Ahern, Tomás B
Timoney, Irene
Sweeney, Cheryl
Kelly, Genevieve
Hughes, Rosalind
Tobin, Anne-Marie
O'Shea, Donal
Kirby, Brian
Issue Date
2016-01-15
Keywords
PSORIASIS
SKIN DISORDERS
MeSH
Clinical Protocols
Dipeptidyl-Peptidase IV Inhibitors
Humans
Prospective Studies
Psoriasis
Quality Control
Sample Size
Sitagliptin Phosphate
Ultraviolet Therapy

Metadata
Show full item record
Citation
Dipeptidyl peptidase-4 inhibition and narrow-band ultraviolet-B light in psoriasis (DINUP): study protocol for a randomised controlled trial. 2016, 17:29 Trials
Publisher
BioMed Central Trials
Journal
Trials
URI
http://hdl.handle.net/10147/621122
DOI
10.1186/s13063-016-1157-z
PubMed ID
26767505
Abstract
Moderate to severe psoriasis is a systemic inflammatory disease associated with insulin resistance, obesity and type 2 diabetes (T2DM). Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that improves glycaemia and has a marketing authorisation for the treatment of T2DM. Non-immunosuppressive therapies that are effective for psoriasis and its associated comorbidities would be a significant advance in the treatment of this chronic disease.
Item Type
Article
Language
en
ISSN
1745-6215
Collections